Login to Your Account



MyoKardia Launches with $38M; Tackles Genetic Heart Disease

By Jennifer Boggs
Managing Editor

Thursday, September 20, 2012
The latest firm launched by Third Rock Ventures, MyoKardia Inc., started its existence with a $38 million Series A financing, disclosed Thursday morning, to translate discoveries of mutations in the heart muscle into personalized therapeutic approaches for treating genetic cardiomyopathy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription